Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio

Stryker (NYSE:SYK) completed the acquisition of Amplitude Vascular Systems on May 7, 2026, adding a next‑generation intravascular lithotripsy (IVL) platform for complex peripheral arterial disease.

Rhea-AI Summary

Stryker (NYSE:SYK) completed the acquisition of Amplitude Vascular Systems on May 7, 2026, adding a next‑generation intravascular lithotripsy (IVL) platform for complex peripheral arterial disease.

The deal brings AVS’s CO₂‑generated pressure wave technology into Stryker’s peripheral vascular portfolio, intended to expand treatment options for challenging arterial disease and support physicians and patient outcomes.

Positive

• Adds next‑generation IVL platform for peripheral arterial disease
• Acquires CO₂‑generated pressure wave technology from Amplitude Vascular Systems
• Expands Stryker's peripheral vascular portfolio and clinical capabilities
• Leverages Stryker scale and resources to support commercialization

Negative

• None.

Argus May 8 session

-2.98% close to close Open Argus

Details

News Market Reaction – SYK

On May 8, the first trading day after this news, SYK closed 2.98% below the previous close.

Data tracked by StockTitan Argus for the May 8 session.

Market Context

This announcement completes Stryker’s acquisition of Amplitude Vascular Systems, adding a next-gener...

Analysis

This announcement completes Stryker’s acquisition of Amplitude Vascular Systems, adding a next-generation IVL platform for complex peripheral arterial disease. It builds on a multi-year strategy of expanding in peripheral vascular and minimally invasive neuro care through targeted M&A. Investors may focus on how the CO₂-based IVL technology integrates into Stryker’s existing peripheral vascular portfolio, its regulatory progress, and any updates in future earnings reports on adoption and margin impact.

Previous Acquisition Reports

5 past events · Latest: Apr 13

Same Type 5 events

1. Apr 13

   AVS deal announcement

   24h Move

   +2.4%

   Definitive agreement to acquire AVS and add next-gen IVL platform.

2. Jan 06

   Facility divestiture

   24h Move

   +5.0%

   VB Spine acquires Stryker’s Cestas spine implant manufacturing facility.

3. Feb 19

   Inari deal close

   24h Move

   +0.8%

   Completion of Inari Medical acquisition, expanding peripheral vascular exposure.

4. Jan 06

   Inari deal announced

   24h Move

   -1.7%

   Definitive agreement to acquire Inari Medical for $80 per share in cash.

5. Sep 20

   NICO acquisition close

   24h Move

   -0.1%

   Completion of NICO acquisition, enhancing minimally invasive brain surgery tools.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

intravascular lithotripsy, peripheral arterial disease, co₂-generated pressure wave technology

3 terms

intravascular lithotripsy medical

"developing a next-generation intravascular lithotripsy (IVL) platform designed to treat"

A catheter-based procedure that uses short pulses of sonic pressure waves delivered inside blood vessels to crack and soften hard calcium deposits that narrow arteries, much like using controlled pebbles to chip away a stubborn rock clog in a pipe. Investors care because the technology can make minimally invasive artery treatments safer and more effective, potentially increasing procedure volumes, device sales, hospital adoption and reimbursement, which affect medical-device company revenues and healthcare costs.

peripheral arterial disease medical

"platform designed to treat complex peripheral arterial disease."

Peripheral arterial disease is a condition where fatty buildup and narrowing in the arteries reduce blood flow to the legs and feet, causing pain, slow wound healing, and higher risk of infection. Investors care because PAD drives demand for diagnostics, drugs, medical devices and procedures, influences healthcare costs and reimbursement decisions, and can affect sales, regulatory milestones and long-term revenue for companies in cardiovascular and wound-care markets.

co₂-generated pressure wave technology technical

"integrating AVS’s innovative CO₂-generated pressure wave technology with Stryker’s"

CO₂-generated pressure wave technology uses controlled releases of compressed carbon dioxide to produce short, powerful bursts of pressure that move material, drive a mechanical effect, or create a shock-like wave for applications such as drug delivery, cleaning, or non‑invasive treatments. For investors, it matters because this method can enable simpler, lower-cost devices with distinct safety, regulatory and performance profiles—factors that affect product adoption, margins and market opportunity much like choosing a different engine for a car.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease.

“This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease,” said Kevin Lobo, Chair and CEO, Stryker. “By integrating AVS’s innovative CO₂-generated pressure wave technology with Stryker’s scale and resources, we are well-positioned to deliver solutions that support physicians and patient outcomes.”

The addition of an IVL platform will strengthen Stryker’s impact in peripheral vascular solutions.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

About Amplitude Vascular Systems (AVS)

Amplitude Vascular Systems (AVS) is a medical device company based in Boston, Mass., focused on treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital, Cue Growth Partners, and others. It was founded in 2017 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at the University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. More information is available at www.avspulse.com.

Contacts

For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or nick.mead@stryker.com

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Stryker (SYK) announce about Amplitude Vascular Systems on May 7, 2026?

Stryker completed the acquisition of Amplitude Vascular Systems on May 7, 2026. According to the company, the purchase adds a next‑generation IVL platform using CO₂‑generated pressure wave technology to Stryker’s peripheral vascular portfolio to address complex arterial disease.

How will the Amplitude Vascular Systems acquisition affect Stryker's peripheral vascular offerings?

The acquisition adds a next‑generation intravascular lithotripsy platform to Stryker's lineup. According to the company, integrating AVS technology aims to expand treatment options for complex peripheral arterial disease and support physicians and patient outcomes.

What technology did Stryker acquire from Amplitude Vascular Systems (SYK)?

Stryker acquired AVS’s CO₂‑generated pressure wave intravascular lithotripsy technology. According to the company, this next‑generation IVL platform is designed specifically to treat complex peripheral arterial disease and complement Stryker’s vascular solutions.

When was the acquisition of Amplitude Vascular Systems by Stryker (SYK) completed?

Stryker completed the acquisition on May 7, 2026. According to the company, the deal immediately integrates AVS’s IVL technology into Stryker’s peripheral vascular portfolio to enhance treatment capabilities.

Does the Stryker acquisition of Amplitude Vascular Systems include clinical or financial results?

The announcement confirms deal completion and technology integration but provides no financial terms or clinical readouts. According to the company, the focus is on adding AVS’s CO₂‑generated IVL platform to its peripheral vascular offerings.